Prolonged Cardiac ECG Patch Versus Conventional Holter For Detecting Atrial Fibrillation After Cerebral Ischemic Event

  • STATUS
    Recruiting
  • End date
    Jan 11, 2025
  • participants needed
    320
  • sponsor
    Sarawak General Hospital
Updated on 5 November 2021
electrocardiogram
stroke
diagnostic procedure
heart disease
fibrillation
12 lead ECG
transient ischemic attack

Summary

The aim of this study is to compare the diagnostic yield of water-resistant, wireless 7-day cardiac ECG patch versus conventional 24-hour Holter recording in detecting paroxysmal atrial fibrillation in patients admitted with acute ischemic stroke or transient ischemic attack of undetermined etiology after completion of a standard clinical stroke workup.

Description

This is a cohort study with a paired comparison between a cardiac ECG patch and conventional Holter system to detect atrial fibrillation in patients with acute ischemic stroke or transient ischemic attack of undetermined etiology. An estimated total of 320 adult patients will be enrolled in this study. Each eligible patient will receive simultaneously a conventional 24h Holter monitoring and a 7d cardiac ECG patch monitoring.

OBJECTIVES

Primary objective:

To determine the diagnostic yield of a cardiac ECG patch compared to conventional Holter monitor for detecting occult paroxysmal atrial fibrillation (AF) within 24 hours in patients admitted with acute ischemic stroke or transient ischemic attack (TIA) of undetermined etiology after completion of a standard clinical stroke work-up.

Secondary objective(s):

  • To determine efficacy of prolonged 7-day ambulatory ECG monitoring (using cardiac ECG patch) compared to conventional 24-hour ambulatory ECG monitoring (using conventional Holter) strategies in detecting paroxysmal AF.
  • To determine if a strategy of a prolonged 7-day ambulatory ECG monitoring results in a change in clinical practice, i.e., more patients are anticoagulated.
  • To assess the time to the first detection of AF within the first 7 days of monitoring.

Exploratory objective(s):

  • To identify predictors of occult AF based on clinical, neuroimaging, echocardiography, and ECG features.
  • To assess feasibility and cost-effectiveness of 7-day cardiac ECG patch monitoring for detecting occult paroxysmal AF.
    SCREENING
  • Written informed consent obtained from patient or guardian
  • Inclusion/Exclusion criteria.
  • Social demographics, Risk factors, Comorbidities, Admission Brain CT/MRI,Stroke status including date and time of index event, date and time of admission, admission modified Rankin scale/NIHSS Score [Data extracted from patient records].
  • 12-lead ECG, Transthoracic Echocardiogram

Eligible patients will be enrolled in the study and proceed with a baseline assessment.

BASELINE ASSESSMENT:

  • Concomitant medication, Oxfordshire classification of stroke and CHA2DS2VAS Score [Data extracted from patient records].
  • Anthropometric measurements and vital signs assessments
  • 24h Holter and 7d Cardiac ECG patch monitoring

FOLLOW UP VISITS:

Follow-up visits will occur at 3 months and 1 year for the efficacy and outcomes for the duration of the study. There will be a total of 2 visits.The investigator/study team will perform the following procedures at each visit where applicable:

  • Clinical examination (NIHSS Score assessment)
  • Review concomitant medications
  • AE/SAE assessment and monitoring
  • Outcomes assessment
  • Health outcome interview with EQ-5D Questionnaire
  • TOAST Classification (at 1 year follow up visit)

Details
Condition Arrhythmia, Atrial Fibrillation, strokes, cerebral, Stroke, Cerebrovascular accident, cerebrovascular accidents, Atrial Fibrillation (Pediatric), Dysrhythmia
Clinical Study IdentifierNCT05082467
SponsorSarawak General Hospital
Last Modified on5 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age 18 years
Diagnosis of acute ischemic stroke or transient ischemic attack (TIA) (WHO definition) of undetermined etiology made by neurologist within 7 days after the index event. The event must be either
an ischemic stroke confirmed by neuroimaging; or
a TIA, defined as involving a focal unilateral motor deficit, speech/language deficit or hemianopia, with symptom duration <24 hours (note: amaurosis fugax/ transient monocular blindness, pure sensory spells, isolated vertigo spells, etc. do not qualify for enrolment given the potential for misdiagnosis of such events)
No AF detected in baseline 12-lead ECG on admission
The following diagnostic test have already been completed as part of clinical routine post-stroke/TIA
Brain imaging with CT or MRI
Transthoracic echocardiography to congenital heart disease and endocarditis
Recurrent stroke/TIA is inclusionary as long as patient meets inclusion/exclusion criteria for study enrolment

Exclusion Criteria

Stroke of unknown time of symptom onset
Modified Rankin Scale 5 on index admission
Previous documented history of primary intracerebral bleeding
Previous documented history of AF or atrial flutter (a remote history of transient AF during perioperative period is not exclusionary)
Skin allergies, conditions, or sensitivities to cardiac patch
Exclusively retinal stroke or retinal TIA event
Pre-existing indication for anticoagulation (eg. History of mechanical heart valve replacement, deep vein thrombosis)
Pre-existing contraindication for permanent anticoagulation (eg. hypocoagulable state)
Echocardiographic findings of congenital heart disease and endocarditis
Indicated for pacemaker, implantable cardiac defibrillator (ICD), CRT device, or an implantable hemodynamic monitoring system
Intravenous drug users (IVDUs)
Life expectancy < 1 year for reasons other than stroke (eg. Metastatic cancer disease)
Concomitant participation in other clinical trials involving investigational medications
Pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note